Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report

Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic my...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Haa-Na, Kang, Min Gyu, Park, Jeong Rang, Hwang, Jin-Yong, Kang, Jung Hun, Lee, Won Seop, Lee, Gyeong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192916/
https://www.ncbi.nlm.nih.gov/pubmed/29361819
http://dx.doi.org/10.4143/crt.2017.529
Descripción
Sumario:Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.

Ejemplares similares